Pulmonary vascular manifestations of mixed connective tissue disease

Rheumatic Disease Clinics of North America

Volumn 31, Issue 3, 2005, Pages 451-464

  Bull, Todd M ^a   Fagan, Karen A ^a   Badesch, David B ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMBRISENTAN; ANGIOTENSIN ANTAGONIST; ANTIINFLAMMATORY AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; DIURETIC AGENT; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; IMMUNOSUPPRESSIVE AGENT; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTANOID; SILDENAFIL; SITAXSETEN; UNCLASSIFIED DRUG; UNIPROST; VASODILATOR AGENT; WARFARIN;

ANEMIA; ANTICOAGULATION; ASPIRATION PNEUMONIA; BIRTH DEFECT; CLINICAL FEATURE; CLINICAL TRIAL; DIAPHRAGM MOVEMENT; DISEASE CLASSIFICATION; DOSE RESPONSE; FLUID RETENTION; GENE MUTATION; HISTOLOGY; HUMAN; HYPOTENSION; INJECTION SITE REACTION; INTERSTITIAL LUNG DISEASE; KIDNEY FAILURE; LIVER TOXICITY; LUNG BLOOD VESSEL; LUNG CIRCULATION; LUNG DISEASE; LUNG HEMORRHAGE; MALE INFERTILITY; MIXED CONNECTIVE TISSUE DISEASE; NONHUMAN; PAIN; PLEURA DISEASE; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; REVIEW; SCLERODERMA; SIDE EFFECT; SURVIVAL RATE; SYNCOPE; SYSTEMIC LUPUS ERYTHEMATOSUS; TERATOGENICITY; TESTIS ATROPHY; VIRUS INFECTION;

HUMANS; HYPERTENSION, PULMONARY; LUNG DISEASES, INTERSTITIAL; MIXED CONNECTIVE TISSUE DISEASE; PLEURAL DISEASES; PULMONARY ALVEOLI; PULMONARY CIRCULATION;

EID: 23444442215     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2005.04.010     Document Type: Review

References (69)

1. G.C. Sharp, W.S. Irvin, and C.M. May Association of antibodies to ribonucleoprotein and Sm antigens with mixed connective-tissue disease, systematic lupus erythematosus and other rheumatic diseases N Engl J Med 295 1976 1149 1154
2. L.J. Rubin Primary pulmonary hypertension N Engl J Med 336 1997 111 117
3. P. Dorfmuller, F. Perros, and K. Balabanian Inflammation in pulmonary arterial hypertension Eur Respir J 22 2003 358 363
4. J.W. Chu, P.N. Kao, and J.L. Faul High prevalence of autoimmune thyroid disease in pulmonary arterial hypertension Chest 122 2002 1668 1673
5. J.H. Morse, R.J. Barst, and M. Fotino Primary pulmonary hypertension, tissue plasminogen activator antibodies, and HLA-DQ7 Am J Respir Crit Care Med 155 1997 274 278
6. R.A. Asherson, E.N. Harris, and R.M. Bernstein Immunological studies in 'primary' idiopathic pulmonary hypertension Eur J Rheumatol Inflamm 7 1984 75 79
7. R.J. Barst, and J.E. Loyd Genetics and immunogenetic aspects of primary pulmonary hypertension Chest 114 Suppl 1998 231S 236S
8. R.H. Young, and G.J. Mark Pulmonary vascular changes in scleroderma Am J Med 64 1978 998 1004
9. C.D. Cool, D. Kennedy, and N.F. Voelkel Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection Hum Pathol 28 1997 434 442
10. F.P. Quismorio Jr, O. Sharma, and M. Koss Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus Semin Arthritis Rheum 13 1984 349 359
11. P.P. Yeo, and R. Sinniah Lupus cor pulmonale with electron microscope and immunofluorescent antibody studies Ann Rheum Dis 34 1975 457 460
12. R.A. Asherson, D. Hackett, and A.E. Gharavi Pulmonary hypertension in systemic lupus erythematosus: a report of three cases J Rheumatol 13 1986 416 420
13. R.A. Asherson, and C.M. Oakley Pulmonary hypertension and systemic lupus erythematosus J Rheumatol 13 1986 1 5
14. A.M. Stupi, V.D. Steen, and G.R. Owens Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis Arthritis Rheum 29 1986 515 524
15. E.K. Li, and L.S. Tam Pulmonary hypertension in systemic lupus erythematosus: clinical association and survival in 18 patients J Rheumatol 26 1999 1923 1929
16. P.J. Fahey, M.J. Utell, and J.J. Condemi Raynaud's phenomenon of the lung Am J Med 76 1984 263 269
17. A. Rozkovec, R. Bernstein, and R.A. Asherson Vascular reactivity and pulmonary hypertension in systemic sclerosis Arthritis Rheum 26 1983 1037 1040
18. L. Seoane, J. Shellito, and D. Welsh Pulmonary hypertension associated with HIV infection South Med J 94 2001 635 639
19. A.M. Pellicelli, G. Barbaro, and F. Palmieri Primary pulmonary hypertension in HIV patients: a systematic review Angiology 52 2001 31 41
20. T.M. Bull, C.D. Cool, and A.E. Serls Primary pulmonary hypertension, Castleman's disease and human herpesvirus-8 Eur Respir J 22 2003 403 407
21. C.D. Cool, P.R. Rai, and M.E. Yeager Expression of human herpesvirus 8 in primary pulmonary hypertension N Engl J Med 349 2003 1113 1122
22. Z. Deng, J.H. Morse, and S.L. Slager Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene Am J Hum Genet 67 2000 737 744
23. R.D. Machado, M.W. Pauciulo, and J.R. Thomson BMPR2 Haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension Am J Hum Genet 68 2001 92 102
24. J.R. Thomson, R.D. Machado, and M.W. Pauciulo Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family J Med Genet 37 2000 741 745
25. M.B. Tew, F.C. Arnett, and J.D. Reveille Mutations of bone morphogenetic protein receptor type II are not found in patients with pulmonary hypertension and underlying connective tissue diseases Arthritis Rheum 46 2002 2829 2830
26. J. Morse, R. Barst, and E. Horn Pulmonary hypertension in scleroderma spectrum of disease: lack of bone morphogenetic protein receptor 2 mutations J Rheumatol 29 2002 2379 2381
27. J.H. Esther, G.C. Sharp, and G. Agia Pulmonary hypertension in patients with connective tissue disease and antibody to nuclear ribonucleoprotein Arthritis Rheum 24 1981 S105
28. J.P. Wiener-Kronish, A.M. Solinger, and M.L. Warnock Severe pulmonary involvement in mixed connective tissue disease Am Rev Respir Dis 124 1981 499 503
29. Y. Hosoda, Y. Suzuki, and M. Takano Mixed connective tissue disease with pulmonary hypertension: a clinical and pathological study J Rheumatol 14 1987 826 830
30. S. Rich, E. Kaufmann, and P.S. Levy The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension N Engl J Med 327 1992 76 81
31. V. Fuster, P.M. Steele, and W.D. Edwards Primary pulmonary hypertension: natural history and the importance of thrombosis Circulation 70 1984 580 587
32. M.A. Alpert, T.A. Pressly, and V. Mukerji Acute and long-term effects of nifedipine on pulmonary and systemic hemodynamics in patients with pulmonary hypertension associated with diffuse systemic sclerosis, the CREST syndrome and mixed connective tissue disease Am J Cardiol 68 1991 1687 1691
33. M. Glikson, A. Pollack, and R. Dresner-Feigin Nifedipine and prazosin in the management of pulmonary hypertension in CREST syndrome Chest 98 1990 759 761
34. J.T. O'Brien, J.A. Hill, and C.J. Pepine Sustained benefit of verapamil in pulmonary hypertension with progressive systemic sclerosis Am Heart J 109 1985 380 382
35. P.P. Sfikakis, M.K. Kyriakidis, and C.G. Vergos Cardiopulmonary hemodynamics in systemic sclerosis and response to nifedipine and captopril Am J Med 90 1991 541 546
36. M.A. Alpert, T.A. Pressly, and V. Mukerji Short- and long-term hemodynamic effects of captopril in patients with pulmonary hypertension and selected connective tissue disease Chest 102 1992 1407 1412
37. G.J. Dusting, S. Moncada, and J.R. Vane Prostacyclin: its biosynthesis, actions, and clinical potential Adv Prostaglandin Thromboxane Leukot Res 10 1982 59 106
38. M. Geraci, B. Gao, and D. Shepherd Pulmonary prostacyclin synthase overexpression by adenovirus transfection and in transgenic mice Chest 114 Suppl 1998 99S
39. T.G. Brock, R.W. McNish, and M. Peters-Golden Arachidonic acid is preferentially metabolized by cyclooxygenase-2 to prostacyclin and prostaglandin E2 J Biol Chem 274 1999 11660 11666
40. E.K. Weir, L.J. Rubin, and S.M. Ayres The acute administration of vasodilators in primary pulmonary hypertension: experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension Am Rev Respir Dis 140 1989 1623 1630
41. L.J. Rubin, J. Mendoza, and M. Hood Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trial Ann Intern Med 112 1990 485 491
42. D.B. Badesch, V.F. Tapson, and M.D. McGoon Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial Ann Intern Med 132 2000 425 434
43. R.J. Barst, L.J. Rubin, and W.A. Long A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group N Engl J Med 334 1996 296 302
44. M.J. McNulty, J.M. Sailstad, and R.P. Steffen The pharmacokinetics and pharmacodynamics of the prostacyclin analog 15AU81 in the anesthetized beagle dog Prostaglandins Leukot Essent Fatty Acids 48 1993 159 166
45. G. Simonneau, R.J. Barst, and N. Galie Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double- blind, randomized, placebo-controlled trial Am J Respir Crit Care Med 165 2002 800 804
46. R.J. Oudiz, R.J. Schilz, and R.J. Barst Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease Chest 126 2004 420 427
47. R.N. Channick, G. Simonneau, and O. Sitbon Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study Lancet 358 2001 1119 1123
48. L.J. Rubin, D.B. Badesch, and R.J. Barst Bosentan therapy for pulmonary arterial hypertension N Engl J Med 346 2002 896 903
49. N.H. Kim, and L.J. Rubin Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension J Cardiovasc Pharmacol Ther 7 2002 9 19
50. O. Sitbon, D.B. Badesch, and R.N. Channick Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study Chest 124 2003 247 254
51. F. Murad Cyclic GMP: synthesis, metabolism, and function. Introduction and some historical comments Adv Pharmacol 26 1994 1 5
52. A. Gibson Phosphodiesterase 5 inhibitors and nitrergic transmission-from zaprinast to sildenafil Eur J Pharmacol 411 2001 1 10
53. E. Michelakis, W. Tymchak, and D. Lien Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide Circulation 105 2002 2398 2403
54. D. Abrams, I. Schulze-Neick, and A.G. Magee Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension Heart 84 2000 E4
55. S. Prasad, J. Wilkinson, and M.A. Gatzoulis Sildenafil in primary pulmonary hypertension N Engl J Med 343 2000 1342
56. L. Stiebellehner, V. Petkov, and K. Vonbank Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension Chest 123 2003 1293 1295
57. M. Karmochkine, B. Wechsler, and P. Godeau Improvement of severe pulmonary hypertension in a patient with SLE Ann Rheum Dis 55 1996 561 562
58. S. Morelli, M. Giordano, and P. De Marzio Pulmonary arterial hypertension responsive to immunosuppressive therapy in systemic lupus erythematosus Lupus 2 1993 367 369
59. H. Groen, H. Bootsma, and D.S. Postma Primary pulmonary hypertension in a patient with systemic lupus erythematosus: partial improvement with cyclophosphamide J Rheumatol 20 1993 1055 1057
60. P. Goupille, L. Fauchier, and D. Babuty Precapillary pulmonary hypertension dramatically improved with high doses of corticosteroids during systemic lupus erythematosus J Rheumatol 21 1994 1976 1977
61. M. Dahl, A. Chalmers, and J. Wade Ten year survival of a patient with advanced pulmonary hypertension and mixed connective tissue disease treated with immunosuppressive therapy J Rheumatol 19 1992 1807 1809
62. U.B. Prakash Respiratory complications in mixed connective tissue disease Clin Chest Med 19 1998 733 746
63. U.B. Prakash, H.S. Luthra, and M.B. Divertie Intrathoracic manifestations in mixed connective tissue disease Mayo Clin Proc 60 1985 813 821
64. W.D. Sullivan, D.J. Hurst, and C.E. Harmon A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease Medicine (Baltimore) 63 1984 92 107
65. T. Kozuka, T. Johkoh, and O. Honda Pulmonary involvement in mixed connective tissue disease: high-resolution CT findings in 41 patients J Thorac Imaging 16 2001 94 98
66. H.C. Hoogsteden, J.J. van Dongen, and T.H. van der Kwast Bilateral exudative pleuritis, an unusual pulmonary onset of mixed connective tissue disease Respiration (Herrlisheim) 48 1985 164 167
67. M.R. Zamora, M.L. Warner, and R. Tuder Diffuse alveolar hemorrhage and systemic lupus erythematosus: clinical presentation, histology, survival, and outcome Medicine (Baltimore) 76 1997 192 202
68. M.J. Germain, and M. Davidman Pulmonary hemorrhage and acute renal failure in a patient with mixed connective tissue disease Am J Kidney Dis 3 1984 420 424
69. M.I. Schwarz, M.R. Zamora, and T.N. Hodges Isolated pulmonary capillaritis and diffuse alveolar hemorrhage in rheumatoid arthritis and mixed connective tissue disease Chest 113 1998 1609 1615